Healthcare
Pfizer deploys Edison’s AI scientist across biopharmaceutical R&D
Pfizer will deploy Edison Scientific’s AI Platform and Kosmos AI scientist across research programs using data from several therapeutic areas.
Edison Scientific announced an agreement to deploy its Edison AI Platform and Kosmos AI scientist across Pfizer’s biopharmaceutical research and development pipeline. Kosmos will access Pfizer data covering oncology, internal medicine, immunology and other areas. The system is intended to support Pfizer scientists, inform research-and-development decisions and accelerate the discovery of potential new medicines. The deployment places an AI system inside a large pharmaceutical company’s existing data and scientific workflows. Its potential value lies in helping researchers analyze information across multiple therapeutic areas and generate insights for scientists. The source does not report specific discoveries, clinical candidates or measurable productivity gains from the deployment. The agreement nevertheless reflects the expansion of AI from isolated research experiments into broader pharmaceutical R&D operations.
Original source: Bio-IT World